Comparative Pharmacology
Head-to-head clinical analysis: KINEVAC versus LUMISIGHT.
Peer-Reviewed Evidence
Head-to-head clinical analysis: KINEVAC versus LUMISIGHT.
KINEVAC vs LUMISIGHT
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
KINEVAC (sincalide) is a synthetic analog of cholecystokinin (CCK) that stimulates gallbladder contraction and pancreatic secretion by binding to CCK-1 receptors on gallbladder smooth muscle and pancreatic acinar cells, leading to release of bile and pancreatic enzymes.
LUMISIGHT is a pegolaptamer that binds to and inhibits the vascular endothelial growth factor (VEGF), thereby reducing angiogenesis and vascular permeability in ocular tissues.
KINEVAC (sincalide) is administered as an IV injection or infusion. For gallbladder contraction/cholecystography: 0.02 mcg/kg IV over 30-60 seconds; may repeat once after 15 minutes if inadequate response. For pancreatic function testing: 0.02 mcg/kg IV over 30-60 seconds followed by secretin stimulation.
1 mg administered intravenously as a single dose prior to identification of suspected malignant lesions during cystoscopy.
None Documented
None Documented
Terminal elimination half-life is 22 hours (range 15-30 hours) in patients with normal renal function. Clinically, this supports once-daily dosing.
Terminal elimination half-life is 4-6 hours in patients with normal renal function; prolonged up to 12-18 hours in moderate to severe renal impairment.
Biliary/fecal: >90% as unchanged drug; renal: <5% as metabolites.
Primarily renal excretion of unchanged drug (60-70%) and hepatic metabolism with biliary/fecal elimination of metabolites (20-25%). Approximately 5-10% is excreted unchanged in feces.
Category C
Category C
Diagnostic Agent, Secretin Analog
Diagnostic Agent